FINLEE Trademark

Trademark Overview


On Tuesday, April 2, 2019, a trademark application was filed for FINLEE with the United States Patent and Trademark Office. The USPTO has given the FINLEE trademark a serial number of 79261971. The federal status of this trademark filing is REGISTERED as of Tuesday, December 24, 2019. This trademark is owned by NOVARTIS AG. The FINLEE trademark is filed in the Pharmaceutical Products category with the following description:

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations, namely, pharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology, namely, pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for use in tissue and organ transplantation, namely, pharmaceutical preparations and substances f...
finlee

General Information


Serial Number79261971
Word MarkFINLEE
Filing DateTuesday, April 2, 2019
Status700 - REGISTERED
Status DateTuesday, December 24, 2019
Registration Number5940924
Registration DateTuesday, December 24, 2019
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 8, 2019

Trademark Statements


Goods and ServicesAnti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations, namely, pharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology, namely, pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for use in tissue and organ transplantation, namely, pharmaceutical preparations and substances for preventing organ rejection; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology, namely, pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Pseudo MarkFIN LEE
Translation of Words in MarkThe wording "FINLEE" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 17, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNOVARTIS AG
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameNOVARTIS AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameNOVARTIS AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events


Event DateEvent Description
Friday, April 24, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, April 6, 2020FINAL DISPOSITION NOTICE SENT TO IB
Monday, April 6, 2020FINAL DISPOSITION PROCESSED
Tuesday, March 24, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, December 24, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, October 8, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 8, 2019PUBLISHED FOR OPPOSITION
Saturday, October 5, 2019NOTIFICATION PROCESSED BY IB
Friday, September 20, 2019REFUSAL PROCESSED BY IB
Wednesday, September 18, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 18, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, September 18, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 4, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, September 4, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 4, 2019REFUSAL PROCESSED BY MPU
Wednesday, August 28, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, August 28, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 28, 2019ASSIGNED TO LIE
Wednesday, August 21, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 21, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, August 20, 2019NON-FINAL ACTION WRITTEN
Thursday, August 15, 2019NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Tuesday, August 13, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, August 13, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 23, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, July 23, 2019APPLICATION FILING RECEIPT MAILED
Monday, July 22, 2019NON-FINAL ACTION WRITTEN
Wednesday, July 17, 2019ASSIGNED TO EXAMINER
Wednesday, July 17, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 15, 2019LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, July 4, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB